In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bringing Urgency And Focus To Takeda: An Interview With Tachi Yamada

Executive Summary

In a wide-ranging interview conducted at Elsevier’s PSA 2013 conference, Takeda’s R&D chief spoke of progress in building a global vaccine business, of the key late-stage assets that will carry the company into the next decade, and of business development priorities in the post-Nycomed era.

Advertisement

Related Content

Takeda Continues Diversification By Hiring French COO From GSK
Takeda Continues Its Diversification By Hiring French COO From GlaxoSmithKline
Vaccine Funding And Access Key To Pharma Success In Developing World
Global Vaccine Market At 10% Growth, Poised For Therapeutic Vaccines
Global Vaccine Market At 10% Growth, Poised For Therapeutic Vaccines
Takeda Adds Medicinal Chemistry Heft To NYC Research Partnership
Takeda’s Strategic Run Up To Nycomed
On Building A Better R&D Machine, Part 2: Pfizer’s R&D Chief Mikael Dolsten Talks Partnering Strategy And Accessing Innovation

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004107

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel